The landscape of diabetes care is shifting. As the global population ages, the clinical focus is moving beyond mere glycaemic control towards preserving functional independence and quality of life. The MID-Frail study (www.midfrail-study.org), a multi-modal intervention trial for frail and pre-frail older adults with type 2 diabetes, represents a landmark effort in this domain [1]. However, while the scientific community rightfully celebrates the ambitious design of this randomised controlled trial (RCT), a more profound achievement lies beneath the surface: the consortium’s strategic approach to publication planning.
Publication planning is defined as a proactive, multi-year strategy to ensure the timely, accurate, and complete dissemination of research findings [2]. It is the architectural blueprint that transforms raw data into a coherent scientific narrative [3]. For the MID-Frail consortium, publication planning is not an afterthought; it is integral to maximizing the €3 billion in potential annual healthcare savings the study estimates for the European Union [1].
Methodology: Why Dissemination Demands a Plan
The MID-Frail protocol is rigorous. Involving a target of 1,718 subjects across 16 partner sites across seven countries, it utilises a cluster-randomised design to compare usual care against a complex intervention involving resistance training, nutritional education, and strict clinical monitoring [1]. The primary endpoint, a one-point change in the Short Physical Performance Battery (SPPB), is a clinically meaningful measure of functional decline [4].
But why is a dedicated publication plan necessary for such a well-designed trial expected to deliver a single conclusion? Because the journey from data to practice is notoriously inefficient. Studies suggest it takes an average of 17 years for clinical research to be fully integrated into routine bedside care [5]. Without a structured plan, even positive results risk languishing in obscurity if not appropriately disseminated.
A formal publication plan addresses this by mapping out the "who, what, and when." As outlined in the Good Publication Practice (GPP3) guidelines, this includes identifying target journals, pre-defining authorship criteria, scheduling submissions to major conferences (like the European Geriatric Medicine Society), and crucially, planning secondary analyses of sub-populations [2][3]. For the MID-Frail study, this strategic layering is evident in their inclusion of its five sub-studies (Sartrain, MID-POW, MetaboFrail, etc.), each designed to answer complementary physiological questions [1].
Return on Investment: Ethics, Impact, and Value
Implementing a publication plan delivers a significant scientific ‘return’ on research investment in three specific areas:
- Scientific Integrity and Transparency: The declaration of Helsinki and the ICMJE recommendations mandate that all results, positive or negative, must be reported and accessible [6]. A publication plan acts as a safeguard against publication bias, ensuring neutral or negative findings regarding hospital admission rates or specific quality of life metrics are still reported [2]. This transparency builds the trust required for evidence-based medicine.
- Maximizing Educational Impact: For a multi-modal intervention, ‘success’ is multi-faceted. A single paper in a general medical journal cannot capture the nuance for all audiences. By pre-planning, the MID-Frail consortium ensures that while the Trialsprotocol paper establishes the methodology, subsequent manuscripts will target specific audiences: physiotherapists learn about the 1RM leg press regimen; health economists see the cost-effectiveness ratios; primary care physicians receive simplified screening tools for frailty [1].
- Facilitating Knowledge Translation: The ultimate goal of the MID-Frail study is to change practice. Effective dissemination plans must reach beyond the library. Modern publication planning encompasses the creation of plain language summaries for patient advocacy groups, press releases for the public, and slide decks for Key Opinion Leaders to present at international summits [7]. The MID-Frail website (midfrail-study.org) serves as a hub for this activity, centralising resources to bridge the gap between the lab and the long-term care facility.
Looking Forward
As the MID-Frail consortium moves from protocol execution to results, the commitment to publication planning will define their legacy. For researchers designing trials today, the lesson is clear: do not wait for the last patient visit to decide how to tell the story.
Mapping your publication strategy at the same time you map your statistical analysis ensures that the immense investment in studies like MID-Frail translates directly into improved mobility, reduced disability, and better care for our ageing population.
References
- Rodriguez-Mañas L, Bayer AJ, Kelly M, et al. An evaluation of the effectiveness of a multi-modal intervention in frail and pre-frail older people with type 2 diabetes - the MID-Frail study: study protocol for a randomised controlled trial. Trials. 2014;15.
- Laver KE, Schofield SJ. Publication planning: promoting an ethics of transparency and integrity in biomedical research. Int J Clin Pract. 2015;69(9):915-921.
- Battisti WP, Wager E, Baltzer L, et al. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Ann Intern Med. 2015;163(6):461-464.
- Kwon S, Perera S, Pahor M, et al. What is a meaningful change in physical performance? Findings from a clinical trial in older adults (the LIFE-P study). J Nutr Health Aging. 2009;13(6):538-544.
- Alper B, Couban R, Dehnbostel J, Robinson K. How to measure the rate of knowledge transfer from clinical trials to clinical practice guidance. Cochrane. 2024.
- International Committee of Medical Journal Editors (ICMJE). Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. Updated December 2024.
- PCORnet. Playbook: Share Your Results. The National Patient-Centered Clinical Research Network. 2025.
